Methods for the treatment of melanoma using compositions of denosumab and PD-1 inhibitor
AssigneeThe University of North Carolina at Chapel Hill
InventorsStergios Moschos, Maureen Su
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods of treating melanoma, such as, e.g., stage III/IV cutaneous or mucosal melanoma, in a subject in need thereof, comprising administering a therapeutically effective amount of denosumab to the subject and optionally co-administering a therapeutically effective amount of a PD-1 inhibitor to the subject; uses of denosumab or a PD-1 inhibitor in the manufacture of a medicament adapted for use in a method described herein; and pharmaceutical compositions comprising denosumab and/or a PD-1 inhibitor for use in a method described herein.
Claims18
A method of treating melanoma in a subject in need thereof, comprising administering to said subject:
- (1) 120 mg denosumab via subcutaneous administration;
- and (2) 480 mg nivolumab or 200 mg pembrolizumab via intravenous administration, wherein the subject does not have bone metastases, and wherein:
- said denosumab comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:11, and light chain comprising the amino acid sequence of SEQ NO:
- 12;
- said nivolumab comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:21, and light chain comprising the amino acid sequence of SEQ NO:
- 22;
- and
- said pembrolizumab comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:31, and light chain comprising the amino acid sequence of SEQ NO:
- 32.
Dependencies are inferred from the claim text.